Director/PDMR Shareholding

27 June 2014

Synergy Health plc ("Synergy", the "Company", or the "Group")

Director/PDMR Shareholding

The Company announces the following transactions by a person discharging managerial responsibilities ("PDMR"), in Synergy Health plc ordinary shares of 0.625 pence each ("Ordinary Shares") and the consequent allocations of Ordinary Shares to the LTIP Co-Invest scheme:

Mr Andrew Mclean, CEO AST and Laboratories, purchased 6,386 Ordinary Shares at a price range of between 1,376 pence and 1,380 pence on 25 June 2014 and allocated these shares to the LTIP Co-Invest scheme. Following the transaction Mr Mclean has an interest in 6,386 Ordinary Shares, representing 0.01% of the Company's issued share capital.

As a result of the above allocation to the Company's Co-Invest Scheme, Mr Mclean has been granted an LTIP Co-Invest option of 12,772 options. The LTIP Co-Invest arrangement requires that the participant to whom the award is to be made invests in Ordinary Shares in the Company and continues to hold those Ordinary Shares throughout the three year measurement period. At the end of the measurement period, depending upon the growth in earnings per share of the Company over the measurement period, the participant will receive a number of "matching" shares at nominal value under the LTIP Co-Invest.

For further information:

Tim Mason, Group Company Secretary +44 (0) 1793 891 862